Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alder Biopharma (ALDR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,306,113
  • Shares Outstanding, K 67,850
  • Annual Sales, $ 1,620 K
  • Annual Income, $ -288,880 K
  • 36-Month Beta 2.59
  • Price/Sales 777.40
  • Price/Cash Flow N/A
  • Price/Book 4.16

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.85 +29.63%
on 06/28/18
19.60 -1.79%
on 07/13/18
+3.05 (+18.83%)
since 06/13/18
3-Month
12.52 +53.69%
on 05/09/18
19.60 -1.79%
on 07/13/18
+4.55 (+30.95%)
since 04/13/18
52-Week
8.60 +123.84%
on 08/21/17
19.60 -1.79%
on 07/13/18
+7.30 (+61.09%)
since 07/13/17

Most Recent Stories

More News
Alder Biopharmac Rises 4.80% on Heavy Volume: Watch For Potential Pullback

Alder Biopharmac (NASDAQ:ALDR) traded in a range yesterday that spanned from a low of $17.50 to a high of $18.75. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high...

ALDR : 19.25 (+3.77%)
Immunogen Inc is Among the Companies in the Biotechnology Industry with the Best Relative Performance (IMGN , ALDR , BLUE , TTOO, TGTX )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

BLUE : 180.60 (+0.17%)
ALDR : 19.25 (+3.77%)
TTOO : 7.65 (+2.00%)
IMGN : 10.12 (-2.13%)
Options Traders Expect Huge Moves in Alder Biopharmaceuticals (ALDR) Stock

Investors in Alder Biopharmaceuticals (ALDR) need to pay close attention to the stock based on moves in the options market lately.

ALDR : 19.25 (+3.77%)
Alder BioPharmaceuticals(R) Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine

- Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate eptinezumab's robust efficacy is further improved at one year following third and fourth quarterly infusions...

ALDR : 19.25 (+3.77%)
Alder BioPharmaceuticals(R) Presents New Six-Month Data for Eptinezumab Demonstrating Improvement in Efficacy in PROMISE 2 Phase 3 Trial for Chronic Migraine

- Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate 43% of patients receiving 300 mg of eptinezumab achieved a 75% or greater reduction of monthly migraine...

ALDR : 19.25 (+3.77%)
Report: Developing Opportunities within Newfield Exploration, Heritage Insurance, AptarGroup, Alder BioPharmaceuticals, TrueCar, and Aduro Biotech -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Newfield Exploration Company...

NFX : 30.10 (+1.31%)
ALDR : 19.25 (+3.77%)
TRUE : 11.54 (+1.14%)
HRTG : 16.82 (+0.36%)
ADRO : 6.85 (unch)
ATR : 94.87 (-0.91%)
Alder BioPharmaceuticals(R) to Present New Data Further Highlighting Eptinezumab's Efficacy Profile for Migraine Prevention at American Headache Society Meeting

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will present updated...

ALDR : 19.25 (+3.77%)
23.4% Return Seen to Date on SmarTrend Alder Biopharmac Call (ALDR)

SmarTrend identified an Uptrend for Alder Biopharmac (NASDAQ:ALDR) on April 12th, 2018 at $14.10. In approximately 2 months, Alder Biopharmac has returned 23.40% as of today's recent price of $17.40.

ALDR : 19.25 (+3.77%)
Teva to Discontinue a Fremanezumab Study on Cluster Headache

Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint....

ALDR : 19.25 (+3.77%)
NVS : 78.78 (-0.20%)
TEVA : 23.29 (-1.85%)
AMGN : 195.91 (+0.94%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (BMRN , ALDR , CYTK , MDXG , ENTA )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CYTK : 9.30 (+1.09%)
ALDR : 19.25 (+3.77%)
BMRN : 103.61 (+0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ALDR with:

Business Summary

Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and...

See More

Key Turning Points

2nd Resistance Point 20.28
1st Resistance Point 19.77
Last Price 19.25
1st Support Level 18.57
2nd Support Level 17.88

See More

52-Week High 19.60
Last Price 19.25
Fibonacci 61.8% 15.40
Fibonacci 50% 14.10
Fibonacci 38.2% 12.80
52-Week Low 8.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar